Paul C. Brown

990 total citations
26 papers, 351 citations indexed

About

Paul C. Brown is a scholar working on Immunology, Small Animals and Molecular Biology. According to data from OpenAlex, Paul C. Brown has authored 26 papers receiving a total of 351 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Immunology, 7 papers in Small Animals and 5 papers in Molecular Biology. Recurrent topics in Paul C. Brown's work include Animal testing and alternatives (7 papers), Immunotoxicology and immune responses (4 papers) and Computational Drug Discovery Methods (3 papers). Paul C. Brown is often cited by papers focused on Animal testing and alternatives (7 papers), Immunotoxicology and immune responses (4 papers) and Computational Drug Discovery Methods (3 papers). Paul C. Brown collaborates with scholars based in United States, Thailand and Germany. Paul C. Brown's co-authors include Ronald L. Wange, Abigail Jacobs, Jackye Peretz, Donna L. Mendrick, Karen Davis‐Bruno, Wafa Harrouk, Todd Bourcier, Shwu‐Luan Lee, Jill Merrill and Ikram Elayan and has published in prestigious journals such as Science, Environmental Health Perspectives and Biochemical Pharmacology.

In The Last Decade

Paul C. Brown

22 papers receiving 331 citations

Peers

Paul C. Brown

CTM

IMMUN

Mark Holbrook United Kingdom

Richard M. Spencer United States

Christopher E. Pollard United Kingdom

Erio Barale-Thomas United States

Jennifer Pierson United States

Payal Rana United States

Daniel Mueller Germany

Stefan Eirefelt Sweden

Marije Niemeijer Netherlands

Elijah J. Weber United States

Mark Holbrook United Kingdom

Paul C. Brown

262 ×2.9

18 ×0.3

77 ×1.2

51 ×0.9

CTM

58 ×1.2

IMMUN

Citations per year, relative to Paul C. Brown Paul C. Brown (= 1×) peers Mark Holbrook

Countries citing papers authored by Paul C. Brown

Since Specialization

Citations

This map shows the geographic impact of Paul C. Brown's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul C. Brown with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul C. Brown more than expected).

Fields of papers citing papers by Paul C. Brown

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul C. Brown. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul C. Brown. The network helps show where Paul C. Brown may publish in the future.

Co-authorship network of co-authors of Paul C. Brown

This figure shows the co-authorship network connecting the top 25 collaborators of Paul C. Brown. A scholar is included among the top collaborators of Paul C. Brown based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul C. Brown. Paul C. Brown is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yao, Jia, Jackye Peretz, Bo Ram Lee, et al.. (2025). FDA/CDER/OND Experience With New Approach Methodologies (NAMs). International Journal of Toxicology. 45(2). 136–156.

Liu, Lisa, et al.. (2025). S.C. delivery of ultra-high concentration (up to 500 mg/mL) protein microparticle suspensions: pharmacokinetics, efficacy, biodistribution, and immunogenicity. Drug Delivery and Translational Research. 16(1). 202–215. 2 indexed citations

Brown, Paul C., Claudia Wrzesinski, Dayton M. Petibone, et al.. (2024). Potential value of animal microphysiological systems. ALTEX. 42(4). 692–699. 1 indexed citations

Mendrick, Donna L., et al.. (2023). Gaps and challenges in nonclinical assessments of pharmaceuticals: An FDA/CDER perspective on considerations for development of new approach methodologies. Regulatory Toxicology and Pharmacology. 139. 105345–105345. 31 indexed citations

Salminen, Alec T., Kelly J. Davis, Robert P. Felton, et al.. (2023). Parallel evaluation of alternative skin barrier models and excised human skin for dermal absorption studies in vitro. Toxicology in Vitro. 91. 105630–105630. 12 indexed citations

Brown, Paul C. & Ronald L. Wange. (2023). Considerations regarding the use of nonhuman primates in assessing safety endpoints for pharmaceuticals. Regulatory Toxicology and Pharmacology. 143. 105449–105449. 11 indexed citations

Wange, Ronald L., Paul C. Brown, & Karen Davis‐Bruno. (2021). Implementation of the principles of the 3Rs of animal testing at CDER: Past, present and future. Regulatory Toxicology and Pharmacology. 123. 104953–104953. 28 indexed citations

Bonzo, Jessica A., Todd Bourcier, Ikram Elayan, et al.. (2020). An FDA/CDER perspective on nonclinical testing strategies: Classical toxicology approaches and new approach methodologies (NAMs). Regulatory Toxicology and Pharmacology. 114. 104662–104662. 112 indexed citations

Jacobs, Abigail & Paul C. Brown. (2015). Regulatory Forum Opinion Piece*. Toxicologic Pathology. 43(5). 605–610. 29 indexed citations

10.

Kasturi, Jyotsna, et al.. (2014). Interconnectivity of Disparate Nonclinical Data Silos for Drug Discovery and Development. Therapeutic Innovation & Regulatory Science. 48(4). 498–506. 3 indexed citations

11.

Cruz, Celia N., Katherine M. Tyner, Kenneth C. Hyams, et al.. (2013). CDER Risk Assessment Exercise to Evaluate Potential Risks from the Use of Nanomaterials in Drug Products. The AAPS Journal. 15(3). 623–628. 9 indexed citations

12.

Brown, Paul C.. (2011). Genes y memes. 4.

13.

Wang, Tao, David Jacobson‐Kram, Anne M. Pilaro, et al.. (2010). ICH Guidelines: Inception, Revision, and Implications for Drug Development. Toxicological Sciences. 118(2). 356–367. 10 indexed citations

14.

Leighton, John K., Paul C. Brown, Amy Ellis, et al.. (2005). Workgroup Report: Review of Genomics Data Based on Experience with Mock Submissions—View of the CDER Pharmacology Toxicology Nonclinical Pharmacogenomics Subcommittee. Environmental Health Perspectives. 114(4). 573–578. 17 indexed citations

15.

Nau, Marion M., et al.. (2001). Cloning and characterization of the 5′ upstream region of the human primary response gene EGR-3. 2(2). 13–20. 1 indexed citations

16.

Schrenk, Dieter, et al.. (1996). Multidrug resistance gene expression in rodents and rodent hepatocytes treated with mitoxantrone. Biochemical Pharmacology. 52(9). 1453–1460. 24 indexed citations

17.

Poland, D., et al.. (1989). Propfan Test Assessment (PTA). NASA STI Repository (National Aeronautics and Space Administration). 3 indexed citations

18.

Brown, Paul C., et al.. (1988). Results of acoustic tests of a prop-fan model. Journal of Aircraft. 25(7). 653–658. 8 indexed citations

19.

Poland, D., et al.. (1988). PTA flight test overview. 24th Joint Propulsion Conference. 8 indexed citations

20.

Brown, Paul C., et al.. (1987). Acoustic test and analysis of a counterrotating prop-fan model. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact